Germany
· Delayed Price · Currency is EUR Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of EUR 18.81 billion. The enterprise value is 28.67 billion.
| Market Cap | 18.81B |
| Enterprise Value | 28.67B |
Important Dates
The next confirmed earnings date is Wednesday, May 6, 2026.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
| Current Share Class | 428.42M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -4.99% |
| Shares Change (QoQ) | -0.65% |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 81.53% |
| Float | 435.88M |
Valuation Ratios
The trailing PE ratio is 28.64 and the forward PE ratio is 7.67.
| PE Ratio | 28.64 |
| Forward PE | 7.67 |
| PS Ratio | 9.29 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 3.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 8.87 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 43.66 |
| EV / Sales | 14.14 |
| EV / EBITDA | 21.12 |
| EV / EBIT | 21.17 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.92.
| Current Ratio | 2.40 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 5.74 |
| Debt / FCF | n/a |
| Interest Coverage | 5.07 |
Financial Efficiency
Return on equity (ROE) is 13.20% and return on invested capital (ROIC) is 5.32%.
| Return on Equity (ROE) | 13.20% |
| Return on Assets (ROA) | 5.15% |
| Return on Invested Capital (ROIC) | 5.32% |
| Return on Capital Employed (ROCE) | 8.21% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 20.26M |
| Profits Per Employee | 6.57M |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +35.30% |
| 50-Day Moving Average | 32.33 |
| 200-Day Moving Average | 34.87 |
| Relative Strength Index (RSI) | 72.72 |
| Average Volume (20 Days) | 218 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.56 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of EUR 2.03 billion and earned 656.62 million in profits. Earnings per share was 1.52.
| Revenue | 2.03B |
| Gross Profit | 2.28B |
| Operating Income | 1.33B |
| Pretax Income | 1.13B |
| Net Income | 656.62M |
| EBITDA | 1.33B |
| EBIT | 1.33B |
| Earnings Per Share (EPS) | 1.52 |
Balance Sheet
The company has 542.96 million in cash and 7.64 billion in debt, giving a net cash position of -7.10 billion.
| Cash & Cash Equivalents | 542.96M |
| Total Debt | 7.64B |
| Net Cash | -7.10B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.27B |
| Book Value Per Share | 12.87 |
| Working Capital | 759.61M |
Cash Flow
| Operating Cash Flow | 2.12B |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.29M |
| Net Borrowing | 816.26M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 112.44%, with operating and profit margins of 65.58% and 32.42%.
| Gross Margin | 112.44% |
| Operating Margin | 65.58% |
| Pretax Margin | 55.68% |
| Profit Margin | 32.42% |
| EBITDA Margin | 65.74% |
| EBIT Margin | 65.58% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.77, which amounts to a dividend yield of 1.84%.
| Dividend Per Share | 0.77 |
| Dividend Yield | 1.84% |
| Dividend Growth (YoY) | -2.39% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 51.03% |
| Buyback Yield | 4.99% |
| Shareholder Yield | 6.84% |
| Earnings Yield | 3.49% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.51 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.51 |
| Piotroski F-Score | 6 |